JMP maintains ViroPharma at outperform

ViroPharma Inc. was maintained at market outperform by JMP Securities analyst Adam Cutler after the company announced encouraging data from its phase 1b study of HCV-796 for the treatment of hepatitis C. In separate news, Cutler was unconcerned by news that Akron Inc. and Cipla may be developing a generic version of ViroPharma's Vancocin, as he believes the barrier to entry for generic Vancocin competition remains high. Shares of the Exton, Pa.-based biotechnology company were down $3.85, or 17.34%, at $18.11 on volume of 16,132,058 shares versus the three-month running average of 2,625,630 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.